This is a summary of the European public assessment report (EPAR) for Novaquin. It explains how the Agency assessed this veterinary medicine to recommend its authorisation in the European Union (EU) and its conditions of use. It is not intended to provide practical advice on how to use Novaquin.
For practical information about using Novaquin, animal owners or keepers should read the package leaflet or contact their veterinarian or pharmacist.
Novaquin : EPAR - Summary for the public (PDF/85.41 KB)Adopted
First published: 08/10/2015
Last updated: 08/10/2015
|Agency product number||
|International non-proprietary name (INN) or common name||
|Anatomical therapeutic chemical veterinary (ATCvet) codes||
Le Vet Beheer B.V.
|Date of issue of marketing authorisation valid throughout the European Union||
24/06/2020 Novaquin - EMEA/V/C/003866 - R/0005
- Annex I - Summary of product characteristics
- Annex IIA - Manufacturing-authorisation holder responsible for batch release
- Annex IIB - Conditions of the marketing authorisation
- Annex IIIA - Labelling
- Annex IIIB - Package leaflet
Please note that the size of the above document can exceed 50 pages.
You are therefore advised to be selective about which sections or pages you wish to print.
Alleviation of inflammation and relief of pain in both acute and chronic musculo-skeletal disorders in horses.